MAPT and Alzheimer disease: Although Aβ and Tau proteins are currently the only well-recognized biomarkers for AD diagnosis, recent evidence suggests that microRNAs (miRNAs) are a promising alternative (Angelucci et al., 2019; Liu et al., 2022).